Rodrigo Jaimovich
Research Subjects
Rodrigo Jaimovich has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- José Miguel Domínguez
Department of Endocrinology, Faculty of Medicine Pontificia Universidad Católica de Chile Santiago Chile
2 shared publications - Annette Madison
Department of Endocrinology, Faculty of Medicine Pontificia Universidad Católica de Chile Santiago Chile
1 shared publication C. Aqueveque
Nuclear Medicine Section, Medicine Department, University of Chile, Clinical Hospital, Santos Dumont 999-1E, Independencia, Santiago, Chile
1 shared publication- Daniela A. Gutiérrez
Cell Signaling Laboratory, Biological Sciences Faculty, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
1 shared publication - Francisco Javier Guarda
Pontificia Universidad Católica de Chile
1 shared publication H. Lavados
Nuclear Medicine Section, Medicine Department, University of Chile, Clinical Hospital, Santos Dumont 999-1E, Independencia, Santiago, Chile
1 shared publication
Latest Publications
- 4 June 2026
- Published by Medwave Estudios Limitada in Medwave
- Vol. 26 (05) , e3179
Persistent elevated thyroglobulin revealing Struma ovarii in a patient treated for papillary thyroid carcinoma: A case report
- 4 June 2026
- Published by Medwave Estudios Limitada in Medwave
- Vol. 26 (05) , e3179
Persistent elevated thyroglobulin revealing Struma ovarii in a patient treated for papillary thyroid carcinoma: A case report
- Open Access
- 27 October 2016
- Published by Wiley in International Journal of Endocrinology
- Vol. 2016, 1-6
Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer
Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration.Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC.Design. Observational prospective study.Patients. DTC patients who underwent thyroidectomy, with or without RAI.Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment.Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi).Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial.
- 27 October 2016
- Published by Wiley in International Journal of Endocrinology
- Vol. 2016, 1-6
Open AccessRadioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer
Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration.Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC.Design. Observational prospective study.Patients. DTC patients who underwent thyroidectomy, with or without RAI.Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment.Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi).Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial.
- 1 January 2010
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 29 (6) , 293-298
Influence of extracardiac activity and perfusion abnormalities on myocardial perfusion gated SPECT parameters: Interobserver analysis
- 1 January 2010
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 29 (6) , 293-298
Influence of extracardiac activity and perfusion abnormalities on myocardial perfusion gated SPECT parameters: Interobserver analysis